Passage Bio Stock Investor Sentiment
| PASG Stock | USD 0.75 0.13 20.97% |
Roughly 58% of all Passage Bio's stockholders are looking to take a long position. The analysis of the overall investor sentiment regarding Passage Bio suggests that some traders are interested. The current market sentiment, together with Passage Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Passage Bio stock news signals to limit their universe of possible portfolio assets.
Passage |
Passage Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Passage Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Passage Bio that are available to investors today. That information is available publicly through Passage media outlets and privately through word of mouth or via Passage internal channels. However, regardless of the origin, that massive amount of Passage data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Passage Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Passage Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Passage Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Passage Bio alpha.
Passage Bio Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Discretionary transaction by Lynx1 Capital Management Lp of tradable shares of Passage Bio subject to Rule 16b-3 | 09/04/2024 |
2 | Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14thInternational Conference on Frontotemporal Dementias | 09/16/2024 |
3 | Disposition of 111400 shares by Orbimed Advisors Llc of Passage Bio at 0.73 subject to Rule 16b-3 | 09/17/2024 |
4 | OrbiMed Advisors sells shares of Passage Bio worth over 146,000 | 09/18/2024 |
5 | Passage Bio to Present at Chardans 8th Annual Genetic Medicines Conference | 09/23/2024 |
6 | Is Passage Bio In A Good Position To Deliver On Growth Plans | 09/24/2024 |
7 | Acquisition by Kassberg Thomas Richard of 1741 shares of Passage Bio at 0.7 subject to Rule 16b-3 | 09/30/2024 |
8 | Disposition of 30000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3 | 10/01/2024 |
9 | Disposition of 50000 shares by Forman Mark S of Passage Bio subject to Rule 16b-3 | 10/03/2024 |
10 | Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene Cell Therapy 31st Annual Conference | 10/24/2024 |
11 | Vestal Point Capital, LP Increases Stake in Passage Bio Inc | 11/14/2024 |
12 | Acquisition by Lynx1 Capital Management Lp of 259998 shares of Passage Bio at 0.5641 subject to Rule 16b-3 | 11/25/2024 |
13 | Acquisition by Lynx1 Capital Management Lp of 167055 shares of Passage Bio at 0.7075 subject to Rule 16b-3 | 11/26/2024 |
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |